Cistero 50mg Injection

Testicular tumour
Ovarian tumour
Bladder tumour
Lung cancer
Head and neck epithelial tumour
Cervical cancer

Cistero 50mg injection may cause various side effects during treatment. There are chances when these reactions become serious; in such cases, contact your doctor immediately. Fever
Infection​
Vomiting
Chills
Hearing loss Skin rash
Back pain
Stomach pain
Swelling on the face
Shortness of breath
Sudden shivering

Take the dose as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This injection is given under the strict supervision of a doctor. Do not self-administer. This injection is given into the veins by a qualified healthcare provider. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider.

An anti-cancer medication, Cistero50mg injection, works by stopping the growth and multiplication of cancer cells by damaging the genetic material (RNA and DNA) of the cancer cells. It does this by binding to the DNA in the cancer cells and preventing them from replicating.

If you miss a dose, consult your healthcare provider. Your provider will suggest a possible way to compensate.

1. Heinhuis KM, Ros W, Kok M, et al. (2023). Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 30(2): 219–235.

2. Yeku O, Russo AL, Lee H, et al. (2024). A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. J Transl Med.18(1): 350,

3. Wu NL, Hingorani S (2025). Outcomes of kidney injury, including dialysis and kidney transplantation in pediatric oncology and hematopoietic cell transplant patients. Pediatr Nephrol 36:2675–2686.

4. World Health Organization. (2023). World Health Organization model list of essential medicines for children: 8th list. World Health Organization.

5. Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V et al (2024). Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife-edge between renoprotection and tumor toxicity. J Biomed Sci 26:25.

6. Kooijmans E, Van der Pal HJ, Pluijm S, Bresters D, Van Dulmen-den Broeder E, Van der Heiden-van der Loo, Margriet, Van den Heuvel-eibrink MM, Kremer L, Loonen J, Louwerens M, Ronckers CM. (2024). TUBULAR DYSFUNCTION AND TREATMENT-RELATED RISK FACTORS IN LONG-TERM CHILDHOOD CANCER SURVIVORS; DCCSS-LATER 2: RENA. In PEDIATRIC NEPHROLOGY 2021 Oct 1 (Vol. 36, No. 10, pp. 3307-3307). ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES: SPRINGER.

7. Iwhiwhu, S.A., Kumar, R., Khan, A.H. et al. (2024). A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice. BMC Nephrol 25, 370.

8. Hayati F, Hossainzadeh M, Shayanpour S, Abedi-Gheshlaghi Z, Beladi Mousavi SS. (2025). Prevention of cisplatin nephrotoxicity. J Nephropharmacol 5(1):57-60.

9. Siddik ZH. (2025). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22(47):7265-79.

10. Arif Akyildiz et al. (2023). The efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: A multicenter study by the Turkish Oncology Group (TOG). JCO 42, e17534-e17534.